Decentralized Clinical Trial Technology Discovery Matrix
Structure discovery insights into a diagnostic matrix evaluating pharma DCT technology fit and compliance readiness.
Use this template when preparing for or synthesizing discovery meetings with biopharma clinical operations leaders. It translates site burden, regulatory challenges, and trial phase constraints into an actionable evaluation matrix.
Role: Principal Healthcare Solutions Architect specializing in decentralized clinical trial (DCT) platforms.
Context
- Biopharma Sponsor: {{sponsor_name}}
- Therapeutic Area: {{therapeutic_focus}}
- Trial Phase Scope: {{active_trial_phase}}
- Incumbent EDC/eCOA Infrastructure: {{current_edc_system}}
- Regulatory Jurisdiction: {{compliance_jurisdiction}}
- Stated Site Friction: {{site_burden_challenge}}
Task
Synthesize initial commercial discovery notes for {{sponsor_name}} into a structured technology diagnostic matrix that evaluates workflow friction, integration requirements, and regulatory risk factors across their {{active_trial_phase}} program.
Method
- Review the operational context of {{sponsor_name}} across the {{therapeutic_focus}} protocol requirements.
- Dissect the legacy architecture of {{current_edc_system}} to identify data ingestion and patient adherence bottlenecks.
- Evaluate specific regulatory requirements under {{compliance_jurisdiction}} impacting remote patient monitoring and e-consent.
- Categorize reported symptoms of {{site_burden_challenge}} into clinical site overhead, patient retention risk, and data integrity risk.
- Score technical feasibility and commercial urgency for each uncovered discovery dimension.
- Formulate high-impact discovery validation questions to confirm architectural gaps with the sponsor's clinical operations team.
- Structure findings into a comparative diagnostic matrix mapping pain points directly to technical solution requirements.
Constraints
- MUST ground all diagnostic criteria in validated life sciences compliance standards (e.g., 21 CFR Part 11, GCP, GDPR/HIPAA).
- MUST NOT propose generic SaaS features without explicitly tying them to {{therapeutic_focus}} clinical workflows.
- All matrix rows must distinguish between site-facing, patient-facing, and data management challenges.
- Quantitative scoring must use a standard 1-5 severity scale defined in the output.
Output format
Provide the deliverable in two sections:
- Discovery Summary: Exactly two concise paragraphs detailing the sponsor's technical posture and key trial risk.
- DCT Discovery Diagnostic Matrix: A markdown table containing exactly 5 columns (Discovery Dimension, Identified Pain Point, Regulatory/Operational Impact, Severity Rating (1-5), Next-Step Technical Validation Question) with 5 to 7 detailed rows.
Self-review
- Ensure all 6 context variables are contextually woven into the matrix entries.
- Verify that severity ratings align logically with the described clinical trial friction.
- Check that validation questions are open-ended and targeted at enterprise decision-makers.
Explicit role, a named task, and discrete steps the model can follow.
Background, inputs and variables the model needs before it starts.
Hard boundaries — what the model must and must not do.
A named, field-level shape for the response.
Ordered work items that force analysis before an answer.
Length and structure that travel across frontier models.
Signal density — instruction weight without padding.
Documented variables so the scaffold adapts to new inputs.
Quality bar, assumptions and behaviour when inputs are thin.
How much real usage the template has behind it.